Refining Treatment Protocols: Expert Perspectives on Deprescribing and Streamlining Diabetes Care for Older Adults

Opinion
Video

Medical professionals evaluate strategies for optimizing diabetes treatment protocols in older adults, emphasizing the critical role of deprescribing in geriatric diabetes care.

Recent Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
Mifepristone Reduced HbA1c, Body Weight in Adults with Hypercortisolism and Inadequately Controlled T2D: CATALYST Trial Treatment Phase

Mifepristone Reduced HbA1c, Body Weight in Adults with Hypercortisolism and Inadequately Controlled T2D: CATALYST Trial Treatment Phase

Sydney Jennings
June 24th 2025
Article

ADA 2025: Mifepristone lowered HbA1c levels by about 1.5% over 24 weeks vs placebo among participants with hypercortisolism and inadequately controlled T2D.

Obesity & Type 2 Diabetes: An Expert Discussion

Obesity & Type 2 Diabetes: An Expert Discussion

Sydney Jennings
June 30th 2023
Podcast

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

Once-Weekly Insulin Efsitora Comparable to Daily Glargine for Hyperglycemia in Adults with Type 2 Diabetes / image credit ADA Julio Rosenstock, MD

Once-Weekly Insulin Efsitora Comparable to Daily Glargine for Hyperglycemia in Adults with Type 2 Diabetes

Grace Halsey
June 23rd 2025
Article

ADA 2025: Insulin efsitora proved noninferior to daily insulin glargine for reducing HbA1c, resulted in fewer episodes of hypoglycemia, and required fewer dose adjustments.

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

Sydney Jennings
July 22nd 2022
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.

Coexisting HTN, T2D in US Adults Doubled Over 2 Decades: Daily Dose / image credit: ©New Africa/AdobeStock

Coexisting HTN, T2D in US Adults Doubled Over 2 Decades: Daily Dose

Sydney Jennings
June 18th 2025
Article

Your daily dose of the clinical news you may have missed.

DASH4D Diet Reduces BP by 4.6 mm Hg in Adults with T2D on Maximal Antihypertensive Therapy

DASH4D Diet Reduces BP by 4.6 mm Hg in Adults with T2D on Maximal Antihypertensive Therapy

Grace Halsey
June 17th 2025
Article

For individuals with T2D, findings are more than numeric; a 5-mm Hg reduction in SBP reduces stroke risk by 14%, CV events by 6%, and heart failure by 8%, authors wrote.

© 2025 MJH Life Sciences

All rights reserved.